CD274 and myelodysplastic syndrome: The results of a phase II, randomized, international, multicenter study (NCT02775903) of azacitidine with or without the PD-L1 antibody durvalumab in frontline therapy for high-risk MDS (cohort 1) or AML (cohort 2) were recently reported [72].